BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 30391163)

  • 21. The essential role of the transporter ABCG2 in the pathophysiology of erythropoietic protoporphyria.
    Wang P; Sachar M; Lu J; Shehu AI; Zhu J; Chen J; Liu K; Anderson KE; Xie W; Gonzalez FJ; Klaassen CD; Ma X
    Sci Adv; 2019 Sep; 5(9):eaaw6127. PubMed ID: 31555729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antisense oligonucleotide-based therapy in human erythropoietic protoporphyria.
    Oustric V; Manceau H; Ducamp S; Soaid R; Karim Z; Schmitt C; Mirmiran A; Peoc'h K; Grandchamp B; Beaumont C; Lyoumi S; Moreau-Gaudry F; Guyonnet-Dupérat V; de Verneuil H; Marie J; Puy H; Deybach JC; Gouya L
    Am J Hum Genet; 2014 Apr; 94(4):611-7. PubMed ID: 24680888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic study in a Singaporean patient with erythropoietic protoporphyria.
    Chuah SY; Tee SI; Pramono ZA; Theng CT
    Photodermatol Photoimmunol Photomed; 2012 Oct; 28(5):269-71. PubMed ID: 22971195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human Erythroid 5-Aminolevulinate Synthase Mutations Associated with X-Linked Protoporphyria Disrupt the Conformational Equilibrium and Enhance Product Release.
    Fratz EJ; Clayton J; Hunter GA; Ducamp S; Breydo L; Uversky VN; Deybach JC; Gouya L; Puy H; Ferreira GC
    Biochemistry; 2015 Sep; 54(36):5617-31. PubMed ID: 26300302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical, biochemical, and genetic study of 11 patients with erythropoietic protoporphyria including one with homozygous disease.
    Herrero C; To-Figueras J; Badenas C; Méndez M; Serrano P; Enríquez-Salamanca R; Lecha M
    Arch Dermatol; 2007 Sep; 143(9):1125-9. PubMed ID: 17875872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ferrochelatase forms an oligomeric complex with mitoferrin-1 and Abcb10 for erythroid heme biosynthesis.
    Chen W; Dailey HA; Paw BH
    Blood; 2010 Jul; 116(4):628-30. PubMed ID: 20427704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Silencing of human ferrochelatase causes abundant protoporphyrin-IX accumulation in colon cancer.
    Kemmner W; Wan K; Rüttinger S; Ebert B; Macdonald R; Klamm U; Moesta KT
    FASEB J; 2008 Feb; 22(2):500-9. PubMed ID: 17875605
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liver metabolomics in a mouse model of erythropoietic protoporphyria.
    Wang P; Sachar M; Guo GL; Shehu AI; Lu J; Zhong XB; Ma X
    Biochem Pharmacol; 2018 Aug; 154():474-481. PubMed ID: 29906468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel null-allele mutations and genotype-phenotype correlation in Argentinean patients with erythropoietic protoporphyria.
    Parera VE; Koole RH; Minderman G; Edixhoven A; Rossetti MV; Batlle A; de Rooij FW
    Mol Med; 2009; 15(11-12):425-31. PubMed ID: 19693296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Results of a pilot study of isoniazid in patients with erythropoietic protoporphyria.
    Parker CJ; Desnick RJ; Bissel MD; Bloomer JR; Singal A; Gouya L; Puy H; Anderson KE; Balwani M; Phillips JD
    Mol Genet Metab; 2019 Nov; 128(3):309-313. PubMed ID: 31395332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A point mutation affecting an SP1 binding site in the promoter of the ferrochelatase gene impairs gene transcription and causes erythropoietic protoporphyria.
    Di Pierro E; Cappellini MD; Mazzucchelli R; Moriondo V; Mologni D; Zanone Poma B; Riva A
    Exp Hematol; 2005 May; 33(5):584-91. PubMed ID: 15850836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distribution of protoporphyrin IX in erythrocytes in a case of acquired erythropoietic protoporphyria.
    Heerfordt IM; Fontenete S; Lerche CM; Wulf HC
    Photodiagnosis Photodyn Ther; 2022 Mar; 37():102629. PubMed ID: 34798346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of FECH gene multiple variations in two Chinese patients with erythropoietic protoporphyria and a review.
    Long ZB; Wang YW; Yang C; Liu G; Du YL; Nie GJ; Chang YZ; Han B
    J Zhejiang Univ Sci B; 2016 Oct.; 17(10):813-820. PubMed ID: 27704751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protoporphyrin accumulation by mitogen stimulated lymphocytes and protoporphyrinogen oxidase activity in patients with porphyria variegata and erythropoietic protoporphyria: evidence for deficiency of protoporphyrinogen oxidase and ferrochelatase in both diseases.
    Siepker LJ; Kramer S
    Br J Haematol; 1985 May; 60(1):65-74. PubMed ID: 3924091
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and molecular epidemiology of erythropoietic protoporphyria in Italy.
    Ventura P; Brancaleoni V; Di Pierro E; Graziadei G; Macrì A; Carmine Guida C; Nicolli A; Rossi MT; Granata F; Fiorentino V; Fustinoni S; Sala R; Pinton PC; Trevisan A; Marchini S; Cuoghi C; Marcacci M; Corradini E; Sorge F; Aurizi C; Savino MG; Cappellini MD; Pietrangelo A
    Eur J Dermatol; 2020 Oct; 30(5):532-540. PubMed ID: 33021473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Iron availability modulates aberrant splicing of ferrochelatase through the iron- and 2-oxoglutarate dependent dioxygenase Jmjd6 and U2AF(65.).
    Barman-Aksözen J; Béguin C; Dogar AM; Schneider-Yin X; Minder EI
    Blood Cells Mol Dis; 2013 Oct; 51(3):151-61. PubMed ID: 23787363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Excessive erythrocyte PPIX influences the hematologic status and iron metabolism in patients with dominant erythropoietic protoporphyria.
    Delaby C; Lyoumi S; Ducamp S; Martin-Schmitt C; Gouya L; Deybach JC; Beaumont C; Puy H
    Cell Mol Biol (Noisy-le-grand); 2009 Feb; 55(1):45-52. PubMed ID: 19268001
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene dosage analysis identifies large deletions of the FECH gene in 10% of families with erythropoietic protoporphyria.
    Whatley SD; Mason NG; Holme SA; Anstey AV; Elder GH; Badminton MN
    J Invest Dermatol; 2007 Dec; 127(12):2790-4. PubMed ID: 17597821
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ferrochelatase Deficiency Abrogated the Enhancement of Aminolevulinic Acid-mediated Protoporphyrin IX by Iron Chelator Deferoxamine.
    Palasuberniam P; Kraus D; Mansi M; Braun A; Howley R; Myers KA; Chen B
    Photochem Photobiol; 2019 Jul; 95(4):1052-1059. PubMed ID: 30767226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incomplete erythropoietic protoporphyria caused by a splice site modulator homozygous IVS3-48C polymorphism in the ferrochelatase gene.
    Mizawa M; Makino T; Nakano H; Sawamura D; Shimizu T
    Br J Dermatol; 2016 Jan; 174(1):172-5. PubMed ID: 26280465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.